Question
Question Posted 06/02/20:
Dear Genetics Core,
A few days ago, I sent you a query re: a few questions I had. However, I still have not received any responses re: my specific questions. Could you please answer my questions below? Thank you so much.
I am planning a study using ADNI DNA methylation data. I am specifically interested in looking at the relationship between DNA methylation age in relation to MCI and AD. I have learned that 640 ADNI participants have methylation data, and that these participants were either cognitively normal, had MCI, or had AD. I have a few questions that I was hoping you could clarify:
1) Among ADNI participants with DNA methylation data, how many had normal cognition, MCI, or AD at the time of the blood draw that was used for DNA methylation?
2) Was this incident normal cognition, MCI, and AD? In other words, were these cases of people who later on developed MCI and AD after the blood draw or did they have these outcomes at the time of the blood draw already?
3) Are the participants who had DNA methylation data still being followed to determine changes in their cognitive outcomes (e.g., transition from normal cognition to MCI/AD)?
4) How many participants with DNA methylation data have information on brain MRI measures (e.g., total brain and regional volumes)?
Dear Genetics Core,
A few days ago, I sent you a query re: a few questions I had. However, I still have not received any responses re: my specific questions. Could you please answer my questions below? Thank you so much.
I am planning a study using ADNI DNA methylation data. I am specifically interested in looking at the relationship between DNA methylation age in relation to MCI and AD. I have learned that 640 ADNI participants have methylation data, and that these participants were either cognitively normal, had MCI, or had AD. I have a few questions that I was hoping you could clarify:
1) Among ADNI participants with DNA methylation data, how many had normal cognition, MCI, or AD at the time of the blood draw that was used for DNA methylation?
2) Was this incident normal cognition, MCI, and AD? In other words, were these cases of people who later on developed MCI and AD after the blood draw or did they have these outcomes at the time of the blood draw already?
3) Are the participants who had DNA methylation data still being followed to determine changes in their cognitive outcomes (e.g., transition from normal cognition to MCI/AD)?
4) How many participants with DNA methylation data have information on brain MRI measures (e.g., total brain and regional volumes)?
Response posted 06/02/20 by Andy Saykin:
The data are available for analysis of these issues as mentioned previously. In brief:
1-Diagnoses may have changed at various time points.
2-Diagnosis at the blood draw visit is available.
3-Follow-up is variable. Some are likely still being followed in ADNI3.
4-All participants should have MRI data.
1-Diagnoses may have changed at various time points.
2-Diagnosis at the blood draw visit is available.
3-Follow-up is variable. Some are likely still being followed in ADNI3.
4-All participants should have MRI data.
